Novartis to buy Regulus Therapeutics for up to $1.7 billion
(Reuters) -Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday. Shares of Regulus surged nearly 15% to $3.86 in …